8-K current report · filed Oct 26, 2026

SUPERNUS PHARMACEUTICALS, INC. (SUPN) 8-K Current Report: October 26, 2026

Item 1.02SUPN overview

Short answer

SUPERNUS PHARMACEUTICALS, INC. (SUPN) filed an 8-K current report with the SEC on October 26, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement). UBS Credit Line terminated October 20, 2026 ahead of the Indivior business combination closing.

SUPERNUS PHARMACEUTICALS, INC. 8-K event analysis

AI summary of each reported item and its exhibits

Item 1.02 · Termination of a Material Definitive Agreement

  • UBS Credit Line terminated October 20, 2026 ahead of the Indivior business combination closing
  • No advances, letters of credit, or other borrowings outstanding at termination
  • No early termination penalties, eliminating potential transaction-related costs
  • UBS security interests released from the pledged securities collateral account
  • Replacement senior secured credit facility expected at merger closing, reshaping combined-company financing

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other SUPERNUS PHARMACEUTICALS, INC. 8-K filings

Get the next SUPN 8-K as it lands

Follow SUPN for push alerts, or ask the research agent what this filing means.